Australia

Admedus secures milestone payment for its unique technology from 4C Medical

Admedus Ltd (ASX:AHZ) has completed the technology transfer of its unique sterilisation method as part of its ADAPT tissue treatment process to 4C Medical Technologies, Inc.

4C Medical is a Minnesota-based developer of AltaValve, a minimally invasive device for mitral valve repair. The technology transfer follows 4C Medical validating the process.

4C Medical will now pay an additional $US1 million ($US 0.44 million previously received) to use the technology to sterilise the ADAPT tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve system device.

“Transformative healing advantages” of ADAPT[hhmc]

The 4C Medical implant utilises tissue processed by Admedus clinically superior ADAPT Tissue Engineering Process for the functioning leaflet component of its valve.

4C Medical will benefit from this technology to optimise function andRead More – Source

[contf]
[contfnew]

Proactiveinvestors

[contfnewc]
[contfnewc]

Related Articles

Back to top button